Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Advaxis, Inc.
  6. Summary
    ADXS   US0076243072

ADVAXIS, INC.

(ADXS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
0.4002(c) 0.37(c) 0.3444(c) 0.3442(c) 0.311 Last
8 384 763 3 398 943 3 378 899 1 852 248 2 868 192 Volume
+4.03% -7.55% -6.92% -0.06% -9.65% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2,99 M - -
Net income 2021 -21,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,83x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -24,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,07x
Yield 2022 -
Capitalization 45,3 M 45,3 M -
Capi. / Sales 2021 15,1x
Capi. / Sales 2022 -
Nbr of Employees 18
Free-Float 99,9%
More Financials
Company
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of Listeria monocytogenes (Lm)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to... 
Sector
Biotechnology & Medical Research
Calendar
12/07 | 10:00amShareholder meeting
More about the company
All news about ADVAXIS, INC.
11/24Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Speci..
AQ
11/22ADVAXIS : Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merge..
PU
11/22ADVAXIS, INC. : Other Events (form 8-K)
AQ
11/22Advaxis Says Nasdaq Gives it Extension to Dec. 20 to Complete Biosight Merger, Comply W..
MT
11/22Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Trans..
AQ
11/19Advaxis Urges Stockholders to Approve Biosight Merger
MT
11/19Advaxis, Inc. Issues Letter to Stockholders
AQ
11/18Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis S..
AQ
11/17ADVAXIS, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-..
AQ
11/15ADVAXIS, INC. : Other Events (form 8-K)
AQ
11/11Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger
AQ
11/09ADVAXIS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
11/09Advaxis, Inc. announced that it expects to receive $21 million in funding
CI
11/08ADVAXIS, INC. : Other Events (form 8-K)
AQ
11/04Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meet..
AQ
More news
News in other languages on ADVAXIS, INC.
11/22Advaxis déclare que le Nasdaq lui accorde un délai supplémentaire jusqu'au 20 décembre ..
11/19Advaxis exhorte ses actionnaires à approuver la fusion avec Biosight
09/10Earnings Flash (ADXS) ADVAXIS annonce un chiffre d'affaires de 250 millions de dollars ..
07/15Advaxis lance un essai de phase 1 sur un traitement précoce du cancer de la prostate
07/06MISE À JOUR SECTORIELLE : Les actions du secteur de la santé attendent la reprise et les b..
More news
Analyst Recommendations on ADVAXIS, INC.
More recommendations
Chart ADVAXIS, INC.
Duration : Period :
Advaxis, Inc. Technical Analysis Chart | ADXS | US0076243072 | MarketScreener
Technical analysis trends ADVAXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,31 $
Average target price 2,25 $
Spread / Average Target 623%
EPS Revisions
Managers and Directors
Kenneth A. Berlin President, Chief Executive Officer, CFO & Director
David Sidransky Chairman
Michael Grace Vice President-Technical Operations
Andres A. GutiÚrrez Chief Medical Officer & Executive Vice President
Roni A. Appel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ADVAXIS, INC.-1.23%50
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745